Biological treatment of NSCLC: The need for conclusive studies

Chest

Volumn 109, Issue 5 SUPPL., 1996, Pages

  Jassem, Jacek ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; INTERFERON; INTERLEUKIN DERIVATIVE; LEVAMISOLE;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; HEALTH CARE NEED; HUMAN; IMMUNOGENICITY; LUNG NON SMALL CELL CANCER; META ANALYSIS; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RISK ASSESSMENT;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; LEVAMISOLE; LUNG NEOPLASMS; TREATMENT OUTCOME;

EID: 0029865196     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. McKneally MF, Maver C, Lininger L, et al. Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer. J Thorac Cardiovasc Surg 1981; 81:485-92
2. Lowe J, Iles PB, Shore DF, et al. Intrapleural BCG in operable lung cancer. Lancet 1980; 1:11-3
3. Mountain CF, Gail MH. Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 1981; 82:649-57
4. The Ludwig Lung Cancer Study Group. Immunostimulation with intrapleural BCG as an adjurant therapy in resected non-small cell lung cancer. Cancer 1986; 58:2411-16
5. Jansen HM, The TH, Orie NG. Adjuvant immunotherapy with BCG in squamous cell bronchial carcinoma. Thorax 1980; 35:781-87
6. Edwards FR. Use of BCG as an immunostimulant after resection of carcinoma of the lung: a 2-year assessment of trial of 500 patients. Thorax 1979; 34:801-06
7. Millar JW, Roscoe P, Pearce SJ, et al. Five-ycar results of a controlled study of BCG immunotherapy after surgical resection in bronchial carcinoma. Thorax 1982; 37:57-60
8. Miller AB, Taylor HE, Baker MA. Oral administration of BCG as an adjuvant to surgical treatment of carcinoma of the bronchus. Can Med Assoc J 1979; 121:45-53
9. Matthay RA, Mahler DA, Beck GJ. Intratumor BCG immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Res 1986; 46:5963-68
10. Amery WK, Cosemans J, Gooszen HC. Adjuvant therapy with levamisole in resectable lung cancer. Rec Results Cancer Res 1977; 68:268-77
11. Anthony HM, Mearns AJ, Mason MK. Levamisole and surgery in bronchial carcinoma patients: increase in deaths from cardiorespiratory failure. Thorax 1979; 34:4-12
12. Study Group for Bronchogenic Carcinoma. Immunopotentiation widi levamisole in resectable bronchogenic carcinoma: a double-blind controlled trial. BMJ 1975; 3:461-64
13. Wright PW, Hill LD, Peterson AV. Preliminary results of combined surgery and adjuvant BCG plus levamisole treatment of resectable lung cancer. Cancer Treat Rep 1978; 62:1671-75
14. Herskovic A, Bauer M, Seydel HG, et al. Postoperative thoracic irradiation with or without levamisole in non-small cell lung cancer: results of a Radiation Therapy Oncology Group study. Int J Radiat Biol Oncol Phys 1988; 14:37-42
15. Fox RM, Woods RL, Tattersall HN. A randomized study of adjuvant immunotherapy with levamisole and Corynebacterium parvum in operable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1980; 6:1043-45
16. Pines A. BCG plus levamisole following irradiation of advanced squamous bronchial carcinoma. Int J Radiat Oncol Biol Phys 1980; 6:1041-45
17. Perez C, Bauer M, Emami BN, et al. Thoracic irradiation with or without levamisole (NSC#177023) in unresectable non-small cell carcinoma of the lung: a phase III randomized trial of the RTOG. Int J Radiat Oncol Biol Phys 1988; 15:1337-46
18. Davis S, Mietlowski W, Rohwedder JJ, et al. Levamisole as an adjuvant to chemotherapy in extensive bronchogenic carcinoma: a Veterans Administration Lung Cancer Group study. Cancer 1982; 50:646-51
19. Rosenberg SA, Lotze MT, Yang JC. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210:474-85
20. Yang SC, Owen-Schaub L, Mendiguren-Rodriguez A. Combination immunotherapy for non-small cell lung cancer. J Thorac Cardiovasc Surg 1990; 99:8-13
21. Bernstein Z, Goldrosen M, Krajewski C. Phase II trial of IL-2/LAK therapy for patients with HD, NHL and NSC lung cancer [abstract]. Proc Am Soc Clin Oncol 1989; 8:A754
22. Kradin RL, Kurnick JT, Lazarus DS, et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989; 15:77-80
23. Scudeletti M, Filaci G, Imro MA, et al. Immunotherapy with intralesional and systemic interleukiu-2 of patients with non-small lung cancer. Cancer Immunol Immunother 1993; 37: 119-24
24. West WH, Tauer KW, Yanelli JR. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316:898-905
25. Ardizzoni A, Bonavia M, Viale M, et al. Biologic and clinical effects of continuous infusion interleukin-2 in patients with non-small cell lung cancer. Cancer 1994; 73:1353-60
26. Jansen RL, Slingerland R, Goey SH, et al. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small cell lung cancer. J Immunother 1992; 12:70-3
27. Lissoni P, Barni S, Rovelli F, et al. Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interlenkin-2 and melatonin: preliminary results. Eur J Cancer 1993; 29A:185-89
28. Sarna GP, Figlin RA. Alpha (human leukocyte) interferon as treatment for non-small cell lung carcinoma of the lung: a phase II trial. J Biol Respir Modif 1983; 2:336-47
29. Leavitt RD, Duffey P, Aisner J. A phase II study of recombinant leukocyte-A interferon in non-small cell lung carcinoma of the lung [abstract]. Proc Am Soc Clin Oncol 1984; 3:52
30. Olesen BK, Ernst P, Nissen MH, et al. Recombinant interferon A (IFL-rA) therapy of small cell and squamous cell carcinoma of the lung: a phase II study. Eur J Cancer Clin Oncol 1987; 23:987-89
31. Figlin RA, Sarna GP. Human leukocyte interferon (IFN): a phase II trial in non-small cell lung cancer and adenocarcinoma of the colon/rectum [abstract]. Proc Am Soc Clin Oncol 1983; 2:45
32. Grunberg SM, Kempf RA, Itri LM, et al. Phase II trial of recombinant interferon alpha plus bleomycin in advanced non-small cell lung cancer. Cancer Treat Rep 1985; 69:1031-32
33. van Zandwijk N, Jassem E, Dubbelmann R, et al. Aerosol application of interferon-alpha in the treatment of bronchioloalveolar carcinoma. Eur J Cancer 1990; 26:738-40
34. Rinaldi DA, Lippman SM, Burris HA III, et al. Phase II study of 13-cis-retinoic acid and alpha-2a interferon in patients with advanced squamous cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1993; 12:353
35. Carmichel J, Fergusson RJ, Wolf CR, et al. Augmentation of cytotoxicity of chemotherapy by human alpha-interferons in human non-small cell lung cancer xenografts. Cancer Res 1986; 464: 916-20
36. Bowman A, Fergusson RJ, Allan SG, et al. Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): a phase II study. Ann Oneol 1990; 1:351-53
37. Kataja V, Yap A, for the NSCLC Collaborative Study Group. Combination of cisplatin (CDDP) and interferon-alpha2a (Roferon-A) in patients with non-small cell lung cancer NSCLC): an open phase II multicentre study. Eur J Cancer 1995; 31A:35-40
38. Ardizzoni A, Salvati F, Rosso R, et al. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Cancer 1993; 72:2929-35
39. Schiller JH, Storer B, Dreicer R, et al. Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatinum in inoperable non-small cell lung cancer. J Natl Cancer Inst 1989; 81:1739-43
40. Zarogoulidis K, Ziogas E, Stergiou V, et al. Randomised addition of interferon-alpha-2alpha in the chemotherapy schedule of NSCLC patients [abstract]. Ann Oncol 1994; 5(suppl 8):156
41. Chang AYC, Keng PC. Potentiation of radiation cytotoxicity by recombinant interferons, a phenomenon associated with increased blockage at the G2-M phase of the cell cycle. Cancer Res 1987; 47:4338-41
42. Maasilta P, Holsti LR, Halme M, et al. Natural alpha-interferon in combination with hyperfractionated radiotherapy in the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 23:863-68
43. Adverse drug reaction of gamma interferon (NSC #600662, ND 2192) reported to Cancer Therapy Evaluation Program. Bethesda, Md: National Cancer Institute, 1992; ADR Nos. 9208151 and 927-872
44. McDonald S, Rubin P, Chang A, et al. Combined betasetron (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1992; 24(suppl):19
45. Dimitrov NV, Conroy J, Suhrland LG. Combination therapy with Corynebacterium parvum and doxorubicin hydrochloride in patients with lung cancer. In: Terry WD, Windhorst D, eds. Immunotherapy of cancer: present status of trials in man. New York: Raven Press, 1978; 181-90
46. Yamamura Y, Ogura T, Sakatani M, et al. Randomized controlled study of adjuvant immunotherapy with Nocardia rubra cell wall skeleton for inoperable lung cancer. Cancer Res 1983; 43: 5575-79
47. Axelrod RS, Havas HF, Murasko DM, et al. Effects of the mixed bacterial vaccine on the immune response of patients with non-small cell lung cancer and refractory malignancies. Cancer 1988; 61:2219-30
48. Whyte RI, Schork MA, Sloan H, et al. Adjuvant treatment using transfer factor for bronchogenic carcinoma: long-term follow-up. Ann Thorac Surg 1992; 53:391-96
49. Hollinshead A, Stewart THM, Takita H, et al. Adjuvant specific active lung cancer immunotherapy trials: tumor associated antigens. Cancer 1987; 60:1249-62
50. Souter RG, Gill PG, Gunning AJ, et al. Failure of specific active immunotherapy in lung cancer. Br J Cancer 1981; 44:496-501
51. Perlin E, Oldham RK, Weese JL. Carcinoma of the lung: immunotherapy with intradermal BCG and allogenic tumor cells. Int J Radiat Oncol Biol Phys 1980; 6:1033-39
52. De-chu T, Carbone DP. Potential application of gene therapy to lung cancer. Semin Oncol 1993; 20:368-73
53. Faradji A, Bohbot A, Schmitt-Gougel M, et al. Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small cell lung cancer: toxicity and immunomodulatory effects. Cancer Immunol Immunother 1991; 33:319-26
54. Tockman MS, Gupta PK, Myers JD. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. J Clin Oncol 1988; 6:1685-93
55. Moylan DJ, Order SE, Zinreich E. Phase I trial of radiolabeled antibody as an adjuvant to radiation therapy for unresectable non-small cell bronchogenic carcinoma: a Radiation Therapy Oncology Group study. Cancer Treat Symp 1985; 2:109-13
56. Dienhart D, Schmelter R, Lear J. Imaging and treatment of non-small cell lung cancer (NSCLC) with monoclonal antibody KC4 [abstract]. Proc Am Soc Clin Oncol 1987; 6:184
57. Dillman RO. Monoclonal antibodies for treating cancer. Ann Intern Med 1989; 111:592-603
58. Herlyn D, Ross AH, Ileopulos D. Induction of specific immunity to human colon carcinoma by anti-idiotypic antibodies to monoclonal antibody CO-17-1A. Eur J Immunol 1987; 17: 1649-52
59. Somasundaram R, Benden A, Zaloudik J, et al. Antigen-specific humoral and cellular immune responses in colorectal carcinoma patients immunized with anti-idiotypic antibody GA733 [abstract]. Proc Am Assoc Cancer Res 1992; 33:331
60. Herlyn D, Linnebach A, Koprowski H, et al. Epitope- and antigen-specific cancer vaccines. Int Rev Immunol 1991; 7: 245-57
61. Garcia de Palazzo IE, Adams GP, Sundareshan P, et al. Expression of mutated epidermal growth factor receptor by non-small cell lung cancer carcinomas. Cancer Res 1993; 53:3217-20